AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02834351 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle Biopsy
Description: A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups.
Study NCT02834351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy
Description: A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups.
Study NCT00387621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
Study NCT00387621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
Study NCT00387621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
Study NCT03969446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02609789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
Study NCT03969446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03969446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT00255749 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: epoetin alfa
Study NCT01517282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOR103
Description: Anti-GM-CSF monoclonal antibody
Study NCT00958282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine/Behavior Therapy
Study NCT00958282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00707616 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: one time 75g oral glucose tolerance test for measurement of insulin secretion and action
Study NCT03583476 — intervention group
Intervention type: DRUG
Intervention: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
Study NCT03817827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: this group will receive Acupuncture for 30 minutes three times per week
Study NCT03860870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol Oral Product
Description: Subjects ingest 4x20 microgram clenbuterol tablets
Study NCT03817827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet supplementary
Description: Diet supplementary with soy product
Study NCT05639582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fractal analysis
Description: fractal analysis is a method that numerically expresses bone changes.
Study NCT03860870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects ingest placebo tablets
Study NCT01494753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2345
Description: One drop at 8.00pm.
Study NCT01494753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin
Description: One drop at 8.00pm.
Study NCT01347515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day.
Study NCT01845688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Tablets & QingReMoShen Granule
Study NCT01845688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan Tablets & Placebo Granule
Study NCT01531088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active medication monitoring
Description: Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
Study NCT00712790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Tablet, 400mg orally, twice daily
Study NCT00712790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: one time treatment and capped at 3.0 Gbq
Study NCT03396003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GALILEI G6 Lens Professional
Description: Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
Study NCT03396003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Pentacam AXL
Description: A single measurement of the eye will be taken using the Oculus Pentacam AXL
Study NCT01153425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Bone Biopsy
Description: MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
Study NCT02579265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid® 20%
Description: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein.
Study NCT01153425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Participants are clinically indicated for treatment.
Study NCT01153425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Participants are clinically indicated for treatment.
Study NCT02174848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution
Description: Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
Study NCT02037412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
Study NCT02037412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
Study NCT03229226 — intervention group
Intervention type: OTHER
Intervention: Verbal versus procedural assessment
Description: Faculty were assessed on both verbal and simulated performance of procedures.
Study NCT04464850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Description: Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin >800 mg/dl: discontinue iron sucrose
Study NCT04464850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron
Description: 1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin >800 mg/dl: discontinue iron fumarate
Study NCT01748201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint lavage and viscosupplementation
Description: The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
Study NCT00778388 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
Study NCT00778388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
Study NCT01517282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to anti-GM-CSF monoclonal antibody
Study NCT03717935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid (EAA) Supplement
Description: Powder supplement
Study NCT03717935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder that will be similar to the essential amino acid supplement
Study NCT02039193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
Study NCT03074344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XLHA+CoQ10
Description: XLHA+CoQ10 for four times a day for 12 weeks.
Study NCT03074344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (HA)
Description: Hyaluronic acid (HA) for four times a day for 12 weeks.
Study NCT01609868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Powder protein modular
Description: Infants will receive powder protein modular to achieve 4 grm/kg/day
Study NCT01609868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid protein modular
Description: Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
Study NCT03425812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To withdraw NSAIDs therapy
Description: NSAIDs therapy will be withdrew after washout period.
Study NCT03425812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: To continue NSAIDs therapy
Description: NSAIDs therapy will be continued.
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Description: Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT02342483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MSM
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV
Description: Efavirenz (EFV) 600 mg tablet administered orally once daily
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV/3TC
Description: Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Atazanavir (ATV) 400 mg tablet administered orally once daily
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily
Study NCT03335982 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transendoscopic enteral tubing in mid-gut
Description: A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
Study NCT02515942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Study NCT02515942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Study NCT02515942 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Empty syringe (without a needle) placed against the eye
Study NCT02338869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial rehabilitation
Study NCT04357210 — intervention group
Intervention type: PROCEDURE
Intervention: fistula tract excision and anal sphincter reconstruction
Description: The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
Study NCT03740425 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Transfusion
Description: Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
Study NCT04882007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)
Study NCT04882007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT04055688 — intervention group
Intervention type: DEVICE
Intervention: Orbeye surgical videomicroscope
Description: The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
Study NCT04055688 — intervention group
Intervention type: DRUG
Intervention: 5-Aminolevulinic Acid
Description: 5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
Study NCT02450227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach - Whole leaf (10 mg lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Study NCT02450227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spinach - Whole leaf (10 mg lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Study NCT02450227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach - Minced (10 mg/lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Study NCT02450227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spinach - Minced (10 mg/lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Study NCT02666183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-C
Description: use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
Study NCT02666183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video-C
Description: use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
Study NCT02666183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Coaching
Description: structured conversations with registered nurses aimed at providing emotional support
Study NCT02666183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Only
Description: Access to a website with caregiving resources, resources for distant care givers, and cancer information
Study NCT02280174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: linagliptin 5 mg/d for12 weeks
Study NCT01433107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine
Description: 1% single application
Study NCT01433107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terbinafine Placebo
Description: single application
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
Study NCT01665274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
Study NCT01347515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Description: Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day.
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAL
Description: Raltegravir (RAL) 400 mg administered administered orally twice daily
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
Study NCT01565889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT03727451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: iNO
Description: inhaled nitric oxide